Efficacy and Safety of SGLT2 Inhibitors and Sotagliflozin in Heart Failure: A Systematic Review and Meta-Analysis of 59 Randomized Controlled Trials

Data, code, and supplementary materials for the systematic review and meta-analysis: "Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis with Trial Sequential Analysis" MAIN FINDINGS:- Primary outcome (CV death or HF hospitalization): HR 0.80 (95% CI 0.73-0.87)- Trial Sequential Analysis: Conclusive evidence (146% of required information size)- NNT: ~58 patients per year- 2 dedicated HFpEF trials included (DELIVER, EMPEROR-Preserved; n=12,251) CONTENTS:- Extracted study data (CSV)- Complete R analysis scripts- All manuscript and supplementary figures (17 PDFs)- RMarkdown source files- Data dictionary REGISTRATION: PROSPERO CRD420251167908 Keywords: SGLT2 inhibitors, heart failure, preserved ejection fraction, HFpEF, meta-analysis, trial sequential analysis, dapagliflozin, empagliflozin